Clinical data show that chronic inflammation at tumor sites is often accompanied by elevated IL-4 levels, and IL-4-producing CD8+ T cells are less effective at tumor clearance compared with their non-IL-4-producing counterparts. This evidence concerns the gene IL4 and neoplasm.